Prazosin, an α1-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease

Neurobiology of Aging

Volumn 34, Issue 4, 2013, Pages 1105-1115

  Katsouri, Loukia ^a   Vizcaychipi, Marcela P ^a   McArthur, Simon ^a   Harrison, Ian ^a   Suárez Calvet, Marc ^b   Lleo, Alberto ^b,c   Lloyd, Dafydd G ^a   Ma, Daqing ^a   Sastre, Magdalena ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Secretase; Adrenergic receptors; Alzheimer's disease; Amyloid ; Inflammation; Mouse brain; Prazosin

Indexed keywords

ADRENERGIC RECEPTOR; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; PRAZOSIN;

ALZHEIMER DISEASE; AMNESIA; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; CELL PROLIFERATION; COGNITION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; MALE; MENTAL DETERIORATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SECRETION; SEX DIFFERENCE; TRANSGENIC MOUSE; TREATMENT DURATION; TREATMENT RESPONSE;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; HUMANS; MALE; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PRAZOSIN; TREATMENT OUTCOME;

EID: 84872293106     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.09.010     Document Type: Article

References (65)

1. Ali K., Middleton M., Pure E., Rader D.J. Apolipoprotein E suppresses the type I inflammatory response in vivo. Circ. Res. 2005, 97:922-927.
2. Arnsten A., Cai J., Goldman-Rakic P. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J. Neurosci. 1988, 8:4287-4298.
3. Arnsten A.F., Jentsch J.D. The alpha-1 adrenergic agonist, cirazoline, impairs spatial working memory performance in aged monkeys. Pharmacol. Biochem. Beh. 1997, 58:55-59.
4. Arnsten A.F., Mathew R., Ubriani R., Taylor J.R., Li B.M. Alpha-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function. Biol. Psychiatry 1999, 45:26-31.
5. Aston-Jones G., Rajkowski J., Cohen J. Locus coeruleus and regulation of behavioral flexibility and attention. Prog. Brain Res. 2000, 126:165-182.
6. Aston-Jones G., Rajkowski J., Kubiak P., Valentino R.J., Shipley M.T. Role of the locus coeruleus in emotional activation. Prog. Brain Res. 1996, 107:379-402.
7. Berridge C.W., Waterhouse B.D. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res. Brain Res. Rev. 2003, 42:33-84.
8. Brown G.C. Mechanisms of inflammatory neurodegeneration: iNOS and NADPH oxidase. Biochem. Soc. Transact. 2007, 35:1119-1121.
9. DeMattos R.B., Brendza R.P., Heuser J.E., Kierson M., Cirrito J.R., Fryer J., Sullivan P.M., Fagan A.M., Han X., Holtzman D.M. Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. Neurochem. Int. 2001, 39:415-425.
10. Doze V.A., Papay R.S., Goldenstein B.L., Gupta M.K., Collette K.M., Nelson B.W., Lyons M.J., Davis B.A., Luger E.J., Wood S.G., Haselton J.R., Simpson P.C., Perez D.M. Long-term alpha1A-adrenergic receptor stimulation improves synaptic plasticity, cognitive function, mood, and longevity. Mol. Pharmacol. 2011, 80:747-758.
11. Fanselow M.S., Dong H.-W. Are the dorsal and ventral hippocampus functionally distinct structures?. Neuron 2010, 65:7-19.
12. Feinstein D.L., Heneka M.T., Gavrilyuk V., Dello Russo C., Weinberg G., Galea E. Noradrenergic regulation of inflammatory gene expression in brain. Neurochem. Int. 2002, 41:357-365.
13. Gibbs M.E., Bowser D.N. Astrocytic adrenoceptors and learning: α1-adrenoceptors. Neurochem. Int. 2010, 57:404-410.
14. Gibbs M.E., Summers R.J. Stimulation of alpha1-adrenoceptors inhibits memory consolidation in the chick. Eur. J. Neurosci. 2001, 14:1369-1376.
15. Gibbs M.E., Summers R.J. Role of adrenoceptor subtypes in memory consolidation. Prog. Neurobiol. 2002, 67:345-391.
16. Gilmartin M.R., Kwapis J.L., Helmstetter F.J. Trace and contextual fear conditioning are impaired following unilateral microinjection of muscimol in the ventral hippocampus or amygdala, but not the medial prefrontal cortex. Neurobiol. Learn. Mem. 2012, 97:452-464.
17. Guardia-Laguarta C., Coma M., Pera M., Clarimón J., Sereno L., Agulló J.M., Molina-Porcel L., Gallardo E., Deng A., Berezovska O., Hyman B.T., Blesa R., Gómez-Isla T., Lleó A. Mild cholesterol depletion reduces amyloid-beta production by impairing APP trafficking to the cell surface. J. Neurochem. 2009, 110:220-230.
18. Heneka M.T., Galea E., Gavriluyk V., Dumitrescu-Ozimek L., Daeschner J., O'Banion M.K., Weinberg G., Klockgether T., Feinstein D.L. Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease. J. Neurosci. 2002, 22:2434-2442.
19. Heneka M.T., Nadrigny F., Regen T., Martinez-Hernandez A., Dumitrescu-Ozimek L., Terwel D., Jardanhazi-Kurutz D., Walter J., Kirchhoff F., Hanisch U.K., Kummer M.P. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:6058-6063.
20. Heneka M.T., Ramanathan M., Jacobs A.H., Dumitrescu-Ozimek L., Bilkei-Gorzo A., Debeir T., Sastre M., Galldiks N., Zimmer A., Hoehn M., Heiss W.D., Klockgether T., Staufenbiel M. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J. Neurosci. 2006, 26:1343-1354.
21. Hertz L., Chen Y., Gibbs M.E., Zang P., Peng L. Astrocytic adrenoceptors: a major drug target in neurological and psychiatric disorders?. Curr. Drug Targets CNS Neurol. Disord. 2004, 3:239-268.
22. Juric D.M., Loncar D., Carman-Krzan M. Noradrenergic stimulation of BDNF synthesis in astrocytes: mediation via alpha1- and beta1/beta2-adrenergic receptors. Neurochem. Int. 2008, 52:297-306.
23. Kalinin S., Gavrilyuk V., Polak P.E., Vasser R., Zhao J., Heneka M.T., Feinstein D.L. Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol. Aging 2007, 28:1206-1214.
24. Kalinin S., Polak P.E., Lin S.X., Sakharkar A.J., Pandey S.C., Feinstein D.L. The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease. Neurobiol. Aging 2012, 33:1651-1663.
25. Kalinin S., Polak P.E., Madrigal J.L., Gavrilyuk V., Sharp A., Chauhan N., Marien M., Colpaert F., Feinstein D.L. Beta-amyloid-dependent expression of NOS2 in neurons: prevention by an alpha2-adrenergic antagonist. Antioxid. Redox. Signal 2006, 8:873-883.
26. Katsouri L., Georgopoulos S. Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model. PloS One 2011, 6:e21880.
27. Kelly M.E., Clay M.A., Mistry M.J., Hsieh-Li H.M., Harmony J.A. Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity. Cell. Immunol. 1994, 159:124-139.
28. Klingner M., Apelt J., Kumar A., Sorger D., Sabri O., Steinbach J., Scheunemann M., Schliebs R. Alterations in cholinergic and non-cholinergic neurotransmitter receptor densities in transgenic Tg2576 mouse brain with β-amyloid plaque pathology. Int. J. Dev. Neurosci. 2003, 21:357-369.
29. Knauber J., Müller W.E. Subchronic treatment with prazosin improves passive avoidance learning in aged mice: possible relationships to α1-receptor up-regulation. J. Neural Transm. 2000, 107:1413-1426.
30. Kötter K., Klein J. Adrenergic modulation of astroglial phospholipase D activity and cell proliferation. Brain Res. 1999, 830:138-145.
31. Lazzaro S.C., Hou M., Cunha C., LeDoux J.E., Cain C.K. Antagonism of lateral amygdala alpha1-adrenergic receptors facilitates fear conditioning and long-term potentiation. Learn. Mem. 2010, 17:489-493.
32. Liao C.-H., Guh J.-H., Chueh S.-C., Yu H.-J. Anti-angiogenic effects and mechanism of prazosin. Prostate 2011, 71:976-984.
33. Liu X., Ding X., Deshmukh G., Liederer B.M., Hop C.E. Use of the cassette-dosing approach to assess brain penetration in drug discovery. Drug Metab. Dispos. 2012, 40:963-969.
34. Maheux J., Vuillier L., Mahfouz M., Rouillard C., Lévesque D. Modulation of haloperidol-induced patterns of the transcription factor Nur77 and Nor-1 expression by serotonergic and adrenergic drugs in the mouse brain. Int. J. Neuropsychopharmacol. 2012, 15:509-521.
35. Mao Z.M., Arnsten A.F., Li B.M. Local infusion of an alpha-1 adrenergic agonist into the prefrontal cortex impairs spatial working memory performance in monkeys. Biol. Psychiatry 1999, 46:1259-1265.
36. Marien M.R., Colpaert F.C., Rosenquist A.C. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res. Brain Res. Rev. 2004, 45:38-78.
37. Milane A., Fernandez C., Dupuis L., Buyse M., Loeffler J.P., Farinotti R., Meininger V., Bensimon G. P-glycoprotein expression and function are increased in an animal model of amyotrophic lateral sclerosis. Neurosci. Lett. 2010, 472:166-170.
38. Mucke L. Neuroscience: Alzheimer's disease. Nature 2009, 461:895-897.
39. Murphy S., Pearce B. Functional receptors for neurotransmitters on astroglial cells. Neuroscience 1987, 22:381-394.
40. Ni Y., Zhao X., Bao G., Zou L., Teng L., Wang Z., Song M., Xiong J., Bai Y., Pei G. Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. Nat. Med. 2006, 12:1390-1396.
41. O'Sullivan J.B., Ryan K.M., Curtin N.M., Harkin A., Connor T.J. Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration. Int. J. Neuropsychopharmacol. 2009, 12:687-699.
42. Palmer A.M. Neurochemical studies of Alzheimer's disease. Neurodegeneration 1996, 5:381-391.
43. Palmer A.M., DeKosky S.T. Monoamine neurons in aging and Alzheimer's disease. J. Neural Transm. Gen. Sect. 1993, 91:135-159.
44. Pearce B., Cambray-Deakin M., Morrow C., Grimble J., Murphy S. Activation of muscarinic and of alpha 1-adrenergic receptors on astrocytes results in the accumulation of inositol phosphates. J. Neurochem. 1985, 45:1534-1540.
45. Pepe M.G., Curtiss L.K. Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In. J. Immunol. 1986, 136:3716-3723.
46. Philipson O., Lannfelt L., Nilsson L.N. Genetic and pharmacological evidence of intraneuronal Abeta accumulation in APP transgenic mice. FEBS Lett. 2009, 583:3021-3026.
47. Pool J.L., Kirby R.S. Clinical significance of α1-adrenoceptor selectivity in the management of benign prostatic hyperplasia. Int. Urol. Nephrol. 2001, 33:407-412.
48. Porter J.T., McCarthy K.D. Astrocytic neurotransmitter receptors in situ and in vivo. Prog. Neurobiol. 1997, 51:439-455.
49. Ramos B.P., Colgan L.A., Nou E., Arnsten A.F.T. β2 adrenergic agonist, clenbuterol, enhances working memory performance in aging animals. Neurobiol. Aging 2008, 29:1060-1069.
50. Rogers J.L., Hunsaker M.R., Kesner R.P. Effects of ventral and dorsal CA1 subregional lesions on trace fear conditioning. Neurobiol. Learn. Mem. 2006, 86:72-81.
51. Sastre M., Dewachter I., Landreth G., Willson T.M., Klockgethers T., van Leuven F., Heneka M.T. Nonsteroidal anti-infammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J. Neurosci. 2003, 23:9796-9804.
52. Sastre M., Klockgether T., Heneka M.T. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int. J. Dev. Neurosci. 2006, 24:167-176.
53. Sastre M., Steiner H., Fuchs K., Capell A., Multhaup G., Condron M.M., Teplow D.B., Haass C. Presenilin-dependent gamma-secretase processing of beta-amyloid precursor at a site corresponding to the S3 cleavage of Notch. EMBO Rep. 2001, 2:835-841.
54. Scullion G.A., Kendall D.A., Marsden C.A., Sunter D., Pardon M.C. Chronic treatment with the alpha2-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APPxPS1 transgenic mice without altering beta-amyloid plaque load or astrocytosis. Neuropharmacology 2011, 60:223-234.
55. Sharp S.I., Ballard C.G., Chen C.P., Francis P.T. Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 2007, 15:435-437.
56. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:13287-13292.
57. Sturchler-Pierrat C., Staufenbiel M. Pathogenic mechanisms of Alzheimer's disease analyzed in the APP23 transgenic mouse model. Ann. NY Acad. Sci. 2000, 920:134-139.
58. Suzuki A., Josselyn S.A., Frankland P.W., Masushige S., Silva A.J., Kida S. Memory reconsolidation and extinction have distinct temporal and biochemical signatures. J. Neurosci. 2004, 24:4787-4795.
59. Vizcaychipi M.P., Lloyd D.G., Wan Y., Palazzo M.G., Maze M., Ma D. Xenon pretreatment may prevent early memory decline after isoflurane anesthesia and surgery in mice. PloS One 2011, 6:e26394.
60. Vizcaychipi M.P., Xu L., Barreto G.E., Ma D., Maze M., Giffard R.G. Heat shock protein 72 overexpression prevents early postoperative memory decline after orthopedic surgery under general anesthesia in mice. Anesthesiology 2011, 114:891-900.
61. Wang L.Y., Shofer J.B., Rohde K., Hart K.L., Hoff D.J., McFall Y.H., Raskind M.A., Peskind E.R. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am. J. Ger. Psychiatry 2009, 17:744-751.
62. Weinshenker D. Functional consequences of locus coeruleus degeneration in Alzheimer's disease. Curr. Alz. Res. 2008, 5:342-345.
63. Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., DeLong M.R. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 1981, 10:122-126.
64. Whitehouse P.J., Struble R.G., Clark A.W., Price D.L. Alzheimer disease: plaques, tangles, and the basal forebrain. Ann. Neurol. 1982, 12:494.
65. Zhang X., Wang W., Bedigian A.V., Coughlin M.L., Mitchison T.J., Eggert U.S. Dopamine receptor D3 regulates endocytic sorting by a Prazosin-sensitive interaction with the coatomer COPI. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:12485-12490.